Literature DB >> 18377826

Immunoregulatory T cells: role and potential as a target in malignancy.

Marc Beyer1, Joachim L Schultze.   

Abstract

Regulatory T cells (T(reg) cells) are a highly specialized subset of immune cells capable of specifically suppressing autoreactive cells and thereby preventing autoimmunity. T(reg) cells also play an important role in limiting the immune reaction in infectious diseases. In the context of malignancies, however, accumulation of T(reg) cells occurs in the tumor microenvironment. T(reg) cells have been associated with prevention of antitumor immunity and the evasion of efficient recognition of tumor antigens. In the past few years, several approaches have been developed to target and deplete T(reg) cells in the context of tumors. Overall, these interventions have the potential to eliminate T(reg) cells and thereby help strengthen antitumor immunity by vaccination.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18377826     DOI： 10.1007/s11912-008-0021-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  50 in total

1.  IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.

Authors:  M Hara; C I Kingsley; M Niimi; S Read; S E Turvey; A R Bushell; P J Morris; F Powrie; K J Wood
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.

Authors:  T Ishida; T Ishii; A Inagaki; H Yano; S Kusumoto; M Ri; H Komatsu; S Iida; H Inagaki; R Ueda
Journal:  Leukemia       Date:  2006-10-12       Impact factor: 11.528

3.  Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy.

Authors:  Mariana Mesel-Lemoine; Mustapha Cherai; Sabine Le Gouvello; Maude Guillot; Virginie Leclercq; David Klatzmann; Véronique Thomas-Vaslin; François M Lemoine
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

4.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

Review 5.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy.

Authors:  Daniel J Powell; Christiaan R de Vries; Tamika Allen; Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

8.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

10.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307
View more
  8 in total

Review 1.  Immunotherapy for the treatment of glioblastoma.

Authors:  Alissa A Thomas; Marc S Ernstoff; Camilo E Fadul
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Infiltrative T regulatory cells in enucleated uveal melanomas.

Authors:  Evan Lagouros; Diva Salomao; Erik Thorland; David O Hodge; Richard Vile; Jose S Pulido
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

Review 3.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

4.  Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.

Authors:  Magis Mandapathil; Benedict Hilldorfer; Miroslaw J Szczepanski; Malgorzata Czystowska; Marta Szajnik; Jin Ren; Stephan Lang; Edwin K Jackson; Elieser Gorelik; Theresa L Whiteside
Journal:  J Biol Chem       Date:  2009-10-26       Impact factor: 5.157

5.  CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma.

Authors:  Magis Mandapathil; Miroslaw Szczepanski; Malgorzata Harasymczuk; Jin Ren; Dongmei Cheng; Edwin K Jackson; Elieser Gorelik; Jonas Johnson; Stephan Lang; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

6.  In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration.

Authors:  Marc Beyer; Beatrix Schumak; Martin R Weihrauch; Bettina Andres; Thomas Giese; Elmar Endl; Percy A Knolle; Sabine Classen; Andreas Limmer; Joachim L Schultze
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

7.  Tumor cell secretion of soluble factor(s) for specific immunosuppression.

Authors:  Arihiro Kano
Journal:  Sci Rep       Date:  2015-03-09       Impact factor: 4.379

8.  CD4+CD25highCD127low/-FoxP3+ Regulatory T Cell Subpopulations in the Bone Marrow and Peripheral Blood of Children with ALL: Brief Report.

Authors:  M Niedźwiecki; O Budziło; M Zieliński; E Adamkiewicz-Drożyńska; L Maciejka-Kembłowska; T Szczepański; P Trzonkowski
Journal:  J Immunol Res       Date:  2018-05-29       Impact factor: 4.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.